Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that the data of its EVIDENCES IV clinical trial of Saroglitazar Magnesium, will be presented at The Liver Meeting® 2019, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), being held in Boston, Massachusetts, USA from 8th to 12th November, 2019.
Earlier Zydus had reported that the EVIDENCES IV clinical trial had achieved the primary end-points in patients with NAFLD and NASH.
Speaking on the development, Mr. Pankaj R. Patel, Chairman, Zydus Group said, "We are pleased that the data of Saroglitazar Mg trial in NASH has been selected for oral presentation at the AASLD's The Liver Meeting. NASH represents a significant public health concern for which there is currently no approved drug therapy, and we are committed to developing this novel molecule for millions of patients suffering from NASH".
Title: "A PHASE 2, PROSPECTIVE, MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY OF SAROGLITAZAR MAGNESIUM 1 MG, 2 MG OR 4 MG VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE AND/OR NONALCOHOLIC STEATOHEPATITIS (EVIDENCES IV)"
Session Title : Late-Breaking Abstract Oral Session II
Presentation Type : Oral, Parallel Session
Session Date and Time : Tuesday, November 12, 2019, 8:00 AM
Presentation Time : 8:45 AM
Location : Auditorium, Hynes Convention Center
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.246.7 as compared to the previous close of Rs. 245.1. The total number of shares traded during the day was 17732 in over 481 trades.
The stock hit an intraday high of Rs. 248.9 and intraday low of 243.3. The net turnover during the day was Rs. 4382664.